Business Context and Reporting Period
Company: MacroGenics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 3, 2017
Event: Entry into an "at-the-market" sales agreement to raise capital.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the potential capital raise:
- Maximum Offering Size: Up to $75,000,000 in aggregate offering price.
- Commission Fee: Up to 3.0% of the gross sales price of shares sold.
Material Changes
The material change reported is the execution of a Sales Agreement with Cowen and Company, LLC. This agreement authorizes the Company to sell shares of its common stock from time to time through Cowen as agent or principal. The shares are offered pursuant to a shelf registration statement (Form S-3) filed on November 2, 2016. The Company retains the right to suspend or terminate the agreement at any time.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the Company has no obligation to sell any shares and may suspend offers or terminate the agreement at any time. Sales may be made in transactions deemed "at the market offerings" on The NASDAQ Global Select Market or as otherwise agreed.
Risks and Contingencies: The filing notes that no sale of shares will occur in any jurisdiction where such an offer would be unlawful prior to registration. The text does not provide specific forward-looking guidance on the timing or volume of sales, nor does it detail specific risks beyond standard securities law compliance.
Investor Verification Checklist
- Verify the current share price and market capitalization to assess the potential dilution impact of a $75 million offering.
- Review the full Sales Agreement (Exhibit 1.1) for specific terms regarding pricing mechanisms and termination rights.
- Check subsequent filings to determine if and when shares have actually been sold under this agreement.
- Confirm the Company's current cash position to understand the necessity of this capital raise.